Access Official Technical PDF

Share Summary:LinkedInEmail

NGS sequencing technologies are judged not only by what they can measure, but also by the cost, time and practical demands of producing results. A platform may offer a notable advantage in read length, accuracy or throughput and still struggle to remain competitive if other characteristics make routine analysis less attractive. The experience of three discontinued high-throughput DNA sequencing technologies illustrates how those trade-offs can shape a platform’s commercial trajectory.

The technologies examined here are 454 Life Sciences’ pyrosequencing, Life Technologies’ SOLiD sequencing and Helicos BioSciences’ true Single Molecule Sequencing (tSMS). Each had distinctive technical features. Their histories show why system evaluation needs to consider the complete workflow rather than a single headline specification.

NGS sequencing technologies compete on more than performance

High-throughput sequencing made it possible to analyze genomes, exomes and transcriptomes with less cost and labor than conventional Sanger sequencing, according to the 2020 conference paper. As sequencing technologies developed, competing platforms differed in how they generated and detected sequence information. Those differences affected practical measures such as read length, analytical duration, reagent requirements and instrument design.

For a laboratory or organization selecting a platform, these factors interact. A method that produces long reads may have drawbacks elsewhere in the workflow. Similarly, high accuracy or throughput does not necessarily compensate for a lengthy run or a high cost per analysis. The cases below demonstrate that commercial viability depends on how well a technology’s advantages align with the needs and economics of its market.

Pyrosequencing: useful capabilities, costly operation

The 454 Life Sciences platform used pyrosequencing, a method based on detecting inorganic pyrophosphate (PPi). The technology offered long reads, fast operation and relatively low sensitivity to GC content. These characteristics distinguished it from competing approaches.

However, the platform also faced significant operating and capital costs. The review identifies expensive reagents as a source of high operating expenditure, the substantial diameter of the microspheres used in the process as another limitation, and the costly optical system as a contributor to capital expense. Semiconductor sequencing was predicted to displace pyrosequencing, and 454 production and instrument support ended in 2016.

The lesson is not that performance advantages lack value. Rather, they must be weighed against the recurring costs of running a system and the investment required to install and maintain its instrumentation. A capable platform can lose ground when its cost structure makes it harder to sustain in routine use.

SOLiD: accuracy traded against read length and time

SOLiD, short for Sequencing by Oligonucleotide Ligation and Detection, was developed in 2005. It relied on repeated ligation of short, fluorescently labeled oligonucleotides. Its reported strengths included high accuracy, up to 99.99%, and throughput of 30 billion base pairs.

Its disadvantages were short reads of 50–75 base pairs and an analysis duration of seven to 14 days. The source reports that Life Technologies announced the end of SOLiD development in 2013. Sequencing by synthesis with fluorescence detection from Illumina subsequently took its place.

This example highlights the importance of matching read characteristics and run duration to the intended application. Accuracy and throughput are important, but they do not alone determine whether a system is suitable. The time required to complete analysis and the length of the resulting reads also affect the practical value of a sequencing workflow.

Helicos tSMS: single-molecule sequencing faced competing limits

Helicos’ true Single Molecule Sequencing technology detected fluorescently labeled nucleotides. Its reads were up to 50 base pairs, and the reported error rate was 3–5%. The review identifies these limitations, alongside the introduction of Pacific Biosciences’ single-molecule sequencing technology in 2010, as factors contributing to a loss of customers. Helicos Biosciences was declared bankrupt at the end of 2012.

The case underscores that introducing a distinct technical approach is not sufficient by itself. A platform must also deliver results that compare favorably on the measures customers consider important. When alternatives emerge, limitations in read length or error rate can become more consequential.

What platform turnover means for system evaluation

Across the three examples, different technical weaknesses led to a similar commercial challenge: disadvantages affected two central considerations identified by the review—analysis cost and the time needed to produce results. The specific trade-offs varied, from expensive reagents and optical equipment to short reads, long analytical cycles and a higher error rate.

When assessing sequencing platforms, technical decision-makers can use these cases to structure their evaluation:

  • Assess the full cost picture. Consider both operating demands, such as reagent expense, and the capital requirements of the instrument.
  • Match read length to the analytical task. A platform’s read characteristics should be considered alongside its other performance measures.
  • Account for analysis time. Run duration can be a significant constraint, particularly when comparing workflows.
  • Evaluate accuracy and throughput together. A strong result in one measure does not erase limitations in another.
  • Consider platform continuity. The discontinuation of production or support can affect the long-term practicality of adopting a system.

Conclusion: evaluate the workflow, not one specification

The histories of 454 pyrosequencing, SOLiD and Helicos tSMS show that sequencing platforms can have meaningful technical advantages and still leave the market. Their outcomes were shaped by combinations of cost, instrument requirements, read length, accuracy and analysis time. For organizations comparing NGS sequencing technologies, the practical implication is clear: evaluate the complete workflow and its trade-offs, rather than selecting a system on the strength of one performance claim.

Access Official Technical PDF

About The Author